0001213900-23-097076.txt : 20231220 0001213900-23-097076.hdr.sgml : 20231220 20231219200814 ACCESSION NUMBER: 0001213900-23-097076 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20231219 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231220 DATE AS OF CHANGE: 20231219 FILER: COMPANY DATA: COMPANY CONFORMED NAME: InMed Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001728328 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39685 FILM NUMBER: 231499085 BUSINESS ADDRESS: STREET 1: SUITE 310, 815 W. HASTINGS STREET CITY: VANCOUVER STATE: A1 ZIP: V6C 1B4 BUSINESS PHONE: (604) 669-7207 MAIL ADDRESS: STREET 1: SUITE 310, 815 W. HASTINGS STREET CITY: VANCOUVER STATE: A1 ZIP: V6C 1B4 8-K 1 ea190383-8k_inmedpharma.htm CURRENT REPORT
false 0001728328 A1 Suite 310 - 815 W. Hastings Street, BC 0001728328 2023-12-19 2023-12-19 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): December 19, 2023

 

InMed Pharmaceuticals Inc.

(Exact Name of Registrant as Specified in Its Charter)

 

British Columbia   001-39685   98-1428279
(State or Other Jurisdiction
of Incorporation)		   (Commission File Number)   (IRS Employer
Identification No.)

 

Suite 310 – 815 W. Hastings Street

Vancouver, B.C.

Canada

   V6C 1B4
(Address of Principal Executive Offices)   (Zip Code)

 

(Registrant’s Telephone Number, Including Area Code): (604) 669-7207

 

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Shares, no par value   INM   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

Item 5.07: Submission of Matters to a Vote of Security Holders.

 

On December 19, 2023, InMed Pharmaceuticals Inc., or the “Corporation”, held its Annual General Meeting of Shareholders. At the meeting, shareholders voted in favor of all items of business, as indicated below:

 

Proposal No. 1—Election of Directors

 

The Corporation’s shareholders voted to elect the following persons to the board of directors of the Corporation, each to serve until the 2024 Annual General Meeting of Shareholders:

 

Nominee   Votes For   % Votes For   Votes Withheld   % Votes Withheld   Broker Non-Votes
Eric A. Adams   160,711   76.09%   50,513   23.91%   1,081,422
Andrew Hull   141,398   66.94%   69,826   33.06%   1,081,422
Janet Grove   141,882   67.17%   69,342   32.83%   1,081,422
Bryan Baldasare   145,659   68.96%   65,565   31.04%   1,081,422
Nicole Lemerond   145,865   69.06%   65,359   30.94%   1,081,422

 

Proposal No. 2—Appointment of Independent Registered Public Accounting Firm

 

The Corporation’s shareholders voted to approve the appointment of Marcum LLP as the independent registered public accounting firm of the Corporation until the 2024 Annual General Meeting of Shareholders or until a successor is named.

 

Votes For   % Votes For   Vote Against   % Votes Against   Abstain  

Broker Non- Votes

1,169,259   90.45%   0   0%   123,387   0

 

1

 

 

Item 7.01 Regulation FD Disclosure.

 

On December 19, 2023, the Corporation issued a press release announcing the voting results of the meeting. A copy of the press release is furnished hereto as Exhibit 99.1.

 

The information set forth in this Item 7.01, including Exhibits 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information set forth in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit 99.1. Press release, dated December 19, 2023
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: December 19, 2023

 

 INMED PHARMACEUTICALS INC.
   
By:/s/ Eric A. Adams               
Name:Eric A. Adams
Title:Chief Executive Officer

 

 

3

 

 EX-99.1 2 ea190383ex99-1_inmedpharma.htm PRESS RELEASE, DATED DECEMBER 19, 2023

Exhibit 99.1 

 

NASDAQ: INM  

 

Suite 310-815 W. Hastings St.

Vancouver, BC, Canada V6C 1B4

Tel: +1.604.669.7207

Email: info@inmedpharma.com

www.inmedpharma.com

 

InMed Announces Results of 2023 Annual General Meeting

 

Vancouver, BC – December 19, 2023 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today confirmed that, at its annual general meeting of shareholders held on December 19, 2023 (the “Meeting”), all of the matters put forward before shareholders for consideration and approval as set out in InMed’s notice of meeting and management information circular, dated October 27, 2023, were approved by the shareholders. A total of 1,292,647 common shares of the Company, representing approximately 38.84% of the Company’s 3,328,191 issued and outstanding common shares, were represented in person or by proxy at the Meeting. In particular, shareholders approved the election of all director nominees to hold office until the next annual meeting of shareholders or until their successors are elected or appointed. Results of the vote for the election of directors at the Meeting are set out as follows:

 

   Votes For   Withheld Votes 
Director  Number   Percentage   Number   Percentage 
Eric A. Adams   160,711    76.09%   50,513    23.91%
Janet Grove   141,882    67.17%   69,342    32.83%
Andrew Hull   141,398    66.94%   69,826    33.06%
Nicole Lemerond   145,865    69.06%   65,359    30.94%
Bryan Baldasare   145,659    68.96%   65,565    31.04%

 

InMed filed a report of voting results on SEDAR at www.sedar.com on December 19, 2023.

 

About InMed:

 

InMed Pharmaceuticals is a global leader in the research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, including clinical and preclinical programs targeting the treatment of diseases with high unmet medical needs. We also have significant know-how in developing proprietary manufacturing approaches to produce cannabinoids for various market sectors. For more information, visit www.inmedpharma.com and www.baymedica.com.

 

Investor Contact:

 

Colin Clancy

Vice President, Investor Relations

and Corporate Communications

T: +1.604.416.0999

E: cclancy@inmedpharma.com

 

Cautionary Note Regarding Forward-Looking Information:

 

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities laws. Forward-looking information is based on management’s current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking information in this news release includes statements about: being a global leader in the manufacturing and development of rare cannabinoids and delivering new treatment alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs.

 

All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

 

 EX-101.SCH 3 inm-20231219.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 inm-20231219_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 inm-20231219_pre.xml XBRL PRESENTATION FILE GRAPHIC 6 ex99-1_001.jpg GRAPHIC begin 644 ex99-1_001.jpg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htm IDEA: XBRL DOCUMENT v3.23.4
Cover
Dec. 19, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Dec. 19, 2023
Entity File Number 001-39685
Entity Registrant Name InMed Pharmaceuticals Inc.
Entity Central Index Key 0001728328
Entity Tax Identification Number 98-1428279
Entity Incorporation, State or Country Code A1
Entity Address, Address Line One Suite 310 - 815 W. Hastings Street,
Entity Address, City or Town Vancouver
Entity Address, State or Province BC
Entity Address, Country CA
Entity Address, Postal Zip Code V6C 1B4
City Area Code 604
Local Phone Number 669-7207
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Shares, no par value
Trading Symbol INM
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
XML 8 ea190383-8k_inmedpharma_htm.xml IDEA: XBRL DOCUMENT 0001728328 2023-12-19 2023-12-19 iso4217:USD shares iso4217:USD shares false 0001728328 A1 Suite 310 - 815 W. Hastings Street, BC 8-K 2023-12-19 InMed Pharmaceuticals Inc. 001-39685 98-1428279 Vancouver CA V6C 1B4 604 669-7207 false false false false Common Shares, no par value INM NASDAQ true false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.4 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://inmedpharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports ea190383-8k_inmedpharma.htm inm-20231219.xsd inm-20231219_lab.xml inm-20231219_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ea190383-8k_inmedpharma.htm": { "nsprefix": "INM", "nsuri": "http://inmedpharma.com/20231219", "dts": { "inline": { "local": [ "ea190383-8k_inmedpharma.htm" ] }, "schema": { "local": [ "inm-20231219.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "inm-20231219_lab.xml" ] }, "presentationLink": { "local": [ "inm-20231219_pre.xml" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 5, "http://xbrl.sec.gov/dei/2023": 5 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://inmedpharma.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2023-12-19", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea190383-8k_inmedpharma.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-19", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea190383-8k_inmedpharma.htm", "first": true, "unique": true } } }, "tag": { "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001213900-23-097076-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-23-097076-xbrl.zip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